ABCL in the 13F filings
Abcellera Biologics Inc · CUSIP 00288U106
- Quarter end
- 31 Dec 2025
- the date the book describes
- Filed
- 19 Feb 2026
- latest of these filings; the earliest 23 Jan 2026
- Managers listing it
- 20
- at least, of 95 tracked, among listed positions
- Comparable managers
- 92
- filed both Q3 2025 and Q4 2025; 3 listed it in both
- Shares listed
- 37,404,126
- combined, among listed positions
- Reported value
- $128m
- combined, at the quarter end
Among the 92 comparable managers: 15 buyers (opened or added shares) and 9 sellers (trimmed or exited), at least, among listed positions. Their net change in shares was -8,049,174.
Managers listing ABCL in Q4 2025
20 of 20 holders
Largest increases and reductions, by shares
Increases
- Tudor Investment Corpexisting position · 1,796,010 shares now+1,065,888
- Jane Street Group LLCexisting position · 1,397,088 shares now+999,944
- Point72 Asset Management LPnew position · 976,507 shares now+976,507
- Citadel Advisors LLCexisting position · 1,834,508 shares now+825,893
- Two Sigma Investments LPexisting position · 5,810,985 shares now+635,843
Reductions
- Renaissance Technologies LLCexisting position · 2,389,229 shares now-971,500
- Millennium Management LLCexisting position · 1,773,539 shares now-656,197
- Arrowstreet Capital LPexisting position · 209,925 shares now-527,020
- Polen Capital Management LLCexisting position · 102,508 shares now-166,740
New positions and exits
New (5)
Exited (5)
- Baillie Gifford & Cowas $52m
- Balyasny Asset Management LLCwas $2.0m
- Caxton Associates LLPwas $1.8m
- Brevan Howard Capital Management LPwas $273k
- Marshall Wace LLPwas $239k
Ownership over time
Tracked managers listing it, at least.
| Quarter | Holders | Reported value | Buyers | Sellers |
|---|---|---|---|---|
| Q4 2020 | 4 | $960m | n.a. | n.a. |
| Q1 2021 | 4 | $837m | n.a. | n.a. |
| Q2 2021 | 3 | $364m | n.a. | n.a. |
| Q3 2021 | 3 | $470m | n.a. | n.a. |
| Q4 2021 | 3 | $376m | n.a. | n.a. |
| Q1 2022 | 3 | $287m | n.a. | n.a. |
| Q2 2022 | 5 | $326m | n.a. | n.a. |
| Q3 2022 | 7 | $270m | n.a. | n.a. |
| Q4 2022 | 3 | $294m | n.a. | n.a. |
| Q1 2023 | 4 | $221m | n.a. | n.a. |
| Q2 2023 | 4 | $226m | n.a. | n.a. |
| Q3 2023 | 3 | $160m | n.a. | n.a. |
| Q4 2023 | 3 | $186m | 1 | 2 |
| Q1 2024 | 3 | $144m | 1 | 1 |
| Q2 2024 | 3 | $81m | 0 | 3 |
| Q3 2024 | 1 | $34m | 0 | 2 |
| Q4 2024 | 2 | $59m | 1 | 1 |
| Q1 2025 | 2 | $55m | 1 | 1 |
| Q2 2025 | 3 | $95m | 1 | 1 |
| Q3 2025 | 5 | $147m | 4 | 0 |
| Q4 2025 | 3 | $63m | 15 | 9 |
| Q1 2026 | 1 | $47m | 9 | 12 |
| Q2 2026 | 2 | $189m | 12 | 13 |
Compare with…
Holders over time, buyers and sellers, and the managers holding both, side by side for up to four stocks.
ABCL and LLY →ABCL and JNJ →ABCL and VRTX →Choose a stock to compare with ABCL →
How much of the picture this is
A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. It shows no shorts, cash, bonds or performance, and it is never today’s portfolio. Large books are listed to their largest positions, so a manager missing from this table may still hold a small position below that line. These are 95 tracked managers, not the institutional market.
Which funds own ABCL, latest filings →Back to the 13F Explorer →